Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04844359 · ClinicalTrials.gov registry record
A Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis
A clinical trial of Hypersensitivity Pneumonitis, sponsored by National Jewish Health.
- Active
- Registry status
- 137
- Enrollment target
- 7
- Study locations
NCT04844359: Active study of Hypersensitivity Pneumonitis, sponsored by National Jewish Health.
NCT04844359 is a study of Hypersensitivity Pneumonitis that is active but no longer recruiting, run by National Jewish Health. The registered enrollment target is 137 participants, below the 357-participant average among 3 other Hypersensitivity Pneumonitis trials with a reported enrollment target (62% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04844359, a study of Hypersensitivity Pneumonitis, is active but no longer recruiting, sponsored by National Jewish Health.
- ACTIVE NOT RECRUITING
- Registry status
- 137 participants
- Enrollment target
- 7
- Study locations
Study Summary
Up to 150 patients with hypersensitivity pneumonitis will be enrolled at 7 clinical centers across the United States. Patients will be followed for 24 months to determine if biomarkers in the blood can predict disease progression.
Conditions Studied
Study Locations (7)
Arizona
- University of Arizona - Tucson
California
- University of California Davis - Sacramento
Colorado
- National Jewish Health - Denver
Illinois
- University of Chicago - Chicago
Minnesota
- Mayo Clinic - Rochester
Texas
- University of Texas Southwestern - Dallas
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2021-01-06 |
| Est. Completion | 2025-07-31 |
What the registry record for NCT04844359 still lists
NCT04844359 is an observational study that tracks outcomes without assigning an intervention. The registered 137 participants enrollment target is mid-sized for trials with a published cap, below the 357-participant average among 3 other Hypersensitivity Pneumonitis trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Hypersensitivity Pneumonitis appearing as the primary indexed condition, and to 0 interventions.
NCT04844359 lists 7 locations in 7 states (Arizona, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT04844359 about?
NCT04844359 is a clinical study titled "A Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis". Up to 150 patients with hypersensitivity pneumonitis will be enrolled at 7 clinical centers across the United States. Patients will be followed for 24 months to determine if biomarkers in the blood can predict disease progression.
What is the current status of trial NCT04844359?
This trial is currently active not recruiting. The enrollment target is 137 participants. The study started on 2021-01-06. Estimated completion is 2025-07-31.
What conditions does trial NCT04844359 study?
This clinical trial studies the following conditions: Hypersensitivity Pneumonitis.
Who is sponsoring clinical trial NCT04844359?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04844359 being conducted?
This trial has 7 study locations across Arizona, California, Colorado, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypersensitivity Pneumonitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05091424 · 137 participants · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- NCT05655182 · 137 participants · Phase 1
A Study of BLB-201 RSV Vaccine in Infants and Children
- NCT06571669 · 137 participants · NA
BOOM-IBD2 Pivotal Clinical Trial
- NCT06644768 · 137 participants · Phase 1
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI